Your browser doesn't support javascript.
loading
Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells.
Watanabe, Keisuke; Terakura, Seitaro; Martens, Anton C; van Meerten, Tom; Uchiyama, Susumu; Imai, Misa; Sakemura, Reona; Goto, Tatsunori; Hanajiri, Ryo; Imahashi, Nobuhiko; Shimada, Kazuyuki; Tomita, Akihiro; Kiyoi, Hitoshi; Nishida, Tetsuya; Naoe, Tomoki; Murata, Makoto.
Afiliação
  • Watanabe K; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya 466-8560, Japan;
  • Terakura S; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya 466-8560, Japan; tseit@med.nagoya-u.ac.jp.
  • Martens AC; Department of Hematology, VU University Medical Center Amsterdam, 1007 MB Amsterdam, the Netherlands; Department of Immunology, University Medical Center Utrecht, 3508 GA Utrecht, the Netherlands;
  • van Meerten T; Department of Hematology, University Medical Center Groningen, 9700 RB Groningen, the Netherlands;
  • Uchiyama S; Division of Advanced Science and Biotechnology, Graduate School of Engineering, Osaka University, Osaka 565-0871, Japan;
  • Imai M; Faculty of Pharmacy, Meijo University, Nagoya 468-8503, Japan;
  • Sakemura R; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya 466-8560, Japan;
  • Goto T; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya 466-8560, Japan;
  • Hanajiri R; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya 466-8560, Japan;
  • Imahashi N; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya 466-8560, Japan;
  • Shimada K; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya 466-8560, Japan; Institute for Advanced Research, Nagoya University, Nagoya 464-8601, Japan; and.
  • Tomita A; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya 466-8560, Japan;
  • Kiyoi H; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya 466-8560, Japan;
  • Nishida T; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya 466-8560, Japan;
  • Naoe T; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya 466-8560, Japan; National Hospital Organization Nagoya Medical Center, Nagoya 460-0001, Japan.
  • Murata M; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya 466-8560, Japan;
J Immunol ; 194(3): 911-20, 2015 Feb 01.
Article em En | MEDLINE | ID: mdl-25520398
The effectiveness of chimeric Ag receptor (CAR)-transduced T (CAR-T) cells has been attributed to supraphysiological signaling through CARs. Second- and later-generation CARs simultaneously transmit costimulatory signals with CD3ζ signals upon ligation, but may lead to severe adverse effects owing to the recognition of minimal Ag expression outside the target tumor. Currently, the threshold target Ag density for CAR-T cell lysis and further activation, including cytokine production, has not yet been investigated in detail. Therefore, we determined the threshold target Ag density required to induce CAR-T cell responses using novel anti-CD20 CAR-T cells with a CD28 intracellular domain and a CD20-transduced CEM cell model. The newly developed CD20CAR-T cells demonstrated Ag-specific lysis and cytokine secretion, which was a reasonable level as a second-generation CAR. For lytic activity, the threshold Ag density was determined to be ∼200 molecules per target cell, whereas the Ag density required for cytokine production of CAR-T cells was ∼10-fold higher, at a few thousand per target cell. CD20CAR-T cells responded efficiently to CD20-downregulated lymphoma and leukemia targets, including rituximab- or ofatumumab-refractory primary chronic lymphocytic leukemia cells. Despite the potential influence of the structure, localization, and binding affinity of the CAR/Ag, the threshold determined may be used for target Ag selection. An Ag density below the threshold may not result in adverse effects, whereas that above the threshold may be sufficient for practical effectiveness. CD20CAR-T cells also demonstrated significant lytic activity against CD20-downregulated tumor cells and may exhibit effectiveness for CD20-positive lymphoid malignancies.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Antígenos de Linfócitos T / Subpopulações de Linfócitos T / Linfócitos T CD8-Positivos / Antígenos de Superfície Idioma: En Revista: J Immunol Ano de publicação: 2015 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Antígenos de Linfócitos T / Subpopulações de Linfócitos T / Linfócitos T CD8-Positivos / Antígenos de Superfície Idioma: En Revista: J Immunol Ano de publicação: 2015 Tipo de documento: Article País de publicação: Estados Unidos